par Kerklaan, Bojana Milojkovic;Diéras, Véronique;Le Tourneau, Christophe;Mergui-Roelvink, Marja;Huitema, Alwin Dr;Rosing, Hilde;Beijnen, Jos J.H.;Marreaud, Sandrine;Govaerts, Anne-Sophie;Piccart-Gebhart, Martine 
;Schellens, Jan J.H.M.;Awada, Ahmad
Référence Cancer chemotherapy and pharmacology, 71, 1, page (53-62)
Publication Publié, 2013-01
;Schellens, Jan J.H.M.;Awada, Ahmad Référence Cancer chemotherapy and pharmacology, 71, 1, page (53-62)
Publication Publié, 2013-01
Article révisé par les pairs
| Titre: |
|
| Auteur: | Kerklaan, Bojana Milojkovic; Diéras, Véronique; Le Tourneau, Christophe; Mergui-Roelvink, Marja; Huitema, Alwin Dr; Rosing, Hilde; Beijnen, Jos J.H.; Marreaud, Sandrine; Govaerts, Anne-Sophie; Piccart-Gebhart, Martine; Schellens, Jan J.H.M.; Awada, Ahmad |
| Informations sur la publication: | Cancer chemotherapy and pharmacology, 71, 1, page (53-62) |
| Statut de publication: | Publié, 2013-01 |
| Sujet CREF: | Cancérologie |
| Pharmacologie | |
| Toxicologie pharmaceutique | |
| Mots-clés: | Activated MAPK pathway |
| Chemotherapy | |
| Farnesyl transferase inhibitor | |
| Her2-positive breast cancer | |
| Lonafarnib | |
| Paclitaxel | |
| Trastuzumab | |
| MeSH keywords: | Adult |
| Aged | |
| Antibodies, Monoclonal, Humanized -- administration & dosage | |
| Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- pharmacokinetics -- therapeutic use | |
| Breast Neoplasms -- drug therapy -- genetics | |
| Dose-Response Relationship, Drug | |
| Female | |
| Humans | |
| Maximum Tolerated Dose | |
| Middle Aged | |
| Paclitaxel -- administration & dosage | |
| Piperidines -- administration & dosage | |
| Pyridines -- administration & dosage | |
| Receptor, ErbB-2 -- genetics | |
| Treatment Outcome | |
| Note générale: | SCOPUS: ar.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:0344-5704 |
| info:doi/10.1007/s00280-012-1972-1 | |
| info:scp/84872279532 | |
| info:pmid/23053259 |
